NICE OKs Xeljanz for individuals with juvenile idiopathic arthritis
Xeljanz is the second drug to be recommended as part of NICE’s new approach to the cost comparison fast track appraisal process
Read More
Tag: Xeljanz
Pfizer’s JAK inhibitor Xeljanz shows benefit in COVID-19 pneumonia
Xeljanz reduced the incidence of death or respiratory failure compared to placebo in hospitalised patients
Read More
EMA’s PRAC to review Xeljanz and recommends fenspiride withdrawl
The committee has announced its latest meeting highlights.
Read More
Pfizer adjusts Xeljanz trial due to pulmonary embolism risk
Pfizer has announced plans to lower its Xeljanz (tofacitinib) trial dosing from 10mg twice-daily to 5mg twice-daily, after pulmonary embolisms were found to be more frequent among patients treated with the higher dose.
Read More
Yescarta rejected among other SMC decisions
Gilead’s CAR-T therapy Yescarta has been rejected by the Scottish Medicines Consortium (SMC) for use on NHS Scotland, but Novartis’ Kymriah was given a green light.
Read More
NICE approves Xeljanz for Ulcerative Colitis
The National Institute for Health and Care Excellence (NICE) has approved Pfizer’s Xeljanz for adults with moderate to severe active ulcerative colitis.
Read More
EU approves Pfizer’s Xeljanz for psoriatic arthritis
The European Commission has approved Pfizer’s Xeljanz as a treatment for psoriatic arthritis (PsA), significantly expanding the drug’s scope.
Read More
AZ’ lung cancer drug Tagrisso backed for first-line use
European regulatory advisors are supporting approval of AstraZeneca’s lung cancer drug Tagrisso in the first-line setting.
Read More
US panel backs Pfizer’s Xeljanz for ulcerative colitis
US regulatory advisors are backing use of Pfizer’s JAK inhibitor Xeljanz to treat adults with moderately to severely active ulcerative colitis (UC).
Read More
Scotland endorses five new therapies for NHS use
Five new medicines are to be funded by the NHS in Scotland, bringing new treatment options for cancer, multiple sclerosis and rheumatoid arthritis, as well as a new contraceptive.
Read More
Pfizer’s Xeljanz wins US nod for psoriatic arthritis
Pfizer Xeljanz and Xeljanz XR have received US marketing clearance for the treatment of adults with active psoriatic arthritis who have failed to respond or are intolerant to methotrexate or other disease-modifying antirheumatic drugs.
Read More
Pfizer bags approval for RA drug Xeljanz
Some patients with moderate to severe forms of rheumatoid arthritis could get access to a new treatment option in Europe following the approval of Pfizer’s oral Janus kinase (JAK) inhibitor Xeljanz.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
